Loading stock data…
$27.86-0.01 (-0.02%)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
Smith & Nephew plc in the Healthcare sector is trading at $27.86 with a market capitalization of $12.7B. Wall Street consensus targets $32.32 (5 analysts), implying a +16.0% move over the next 12 months. The stock is currently near its 52-week low of $26.12, remaining 9.5% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 78 is overbought against a weak tape. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Me...